Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07553871

Comparative Study on the Medium- and Long-term Benefits of Prosthesis Selection in Total Knee Arthroplasty

This retrospective real-world study aims to compare the medium- and long-term clinical outcomes, safety, and economic benefits of different knee prosthesis brands used in primary unilateral total knee arthroplasty (TKA) at our hospital. The study will include adult patients who underwent first-time unilateral TKA between January 1, 2022 and December 31, 2025. Outcomes such as postoperative knee function, complications, length of hospital stay, quality of life, and medical costs will be evaluated. The results are expected to provide evidence to support prosthesis selection and optimize healthcare resource allocation.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

This is a single-center, retrospective, open-label, non-randomized cohort study based on real-world clinical data from the Second Affiliated Hospital of Wenzhou Medical University.

The study population will include all adult patients who underwent first-time unilateral primary total knee arthroplasty (TKA) between January 1, 2022 and December 31, 2025. Patients who underwent revision arthroplasty, simultaneous bilateral arthroplasty, concomitant arthroplasty of other joints, arthroplasty for tumor or acute trauma, or who had severely incomplete data will be excluded.

Participants will be grouped according to the prosthesis brand and model documented in the operative record. Baseline variables will include age, sex, body mass index, preoperative diagnosis, ASA classification, comorbidities, and preoperative knee function score. Surgery-related variables will include prosthesis brand and model, fixation method, operative duration, intraoperative blood loss, surgeon seniority, use of a tourniquet, and drainage duration.

The primary outcome will be knee function score at 1 year after surgery, assessed using the HSS score or KSS score. Secondary outcomes will include postoperative complications, length of hospital stay, functional recovery, quality of life, and patient-reported outcomes at different postoperative time points. Economic outcomes will include direct medical costs, direct non-medical costs, indirect costs, and cost-effectiveness analysis. Safety outcomes will include all postoperative adverse events.

The objective of this study is to comprehensively compare the medium- and long-term clinical effectiveness, safety, and economic benefits of different prosthesis brands used in TKA, and to provide evidence to support clinical prosthesis selection and healthcare resource optimization.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age >= 18 years.
  • Diagnosis of end-stage knee osteoarthritis, rheumatoid arthritis, or other conditions meeting the indication for TKA.
  • First-time unilateral knee arthroplasty.
  • Complete medical records, including perioperative records, prosthesis model records, detailed cost information, and regular postoperative follow-up records.

Exclusion criteria

  • Revision knee arthroplasty, simultaneous bilateral arthroplasty, or concomitant arthroplasty of other joints.
  • Arthroplasty performed for non-degenerative conditions such as tumour or acute trauma.
  • Perioperative death or loss to follow-up.
  • Severely incomplete clinical data that preclude valid analysis.

Treatment and study plan

Primary outcomes

  1. Knee Function Score at 1 Year After Surgery

    Time frame: 1 year after surgery

    The KSS ranges from 0 to 100, with higher scores indicating better knee function.

Secondary outcomes

  1. Postoperative Complications

    Time frame: Perioperative through 5 years after surgery

    Complications occurring after primary unilateral total knee arthroplasty, including but not limited to infection, deep vein thrombosis, periprosthetic fracture, and prosthesis loosening. Complications will be assessed during the perioperative period and at 1 month, 3 months, 6 months, 1 year, 3 years, and 5 years after surgery.

  2. Length of Postoperative Hospital Stay

    Time frame: From surgery to hospital discharge, assessed up to 30 days

    Length of hospital stay after primary unilateral total knee arthroplasty.

  3. Postoperative Knee Function Score

    Time frame: 1 month, 3 months, 6 months, 3 years, and 5 years after surgery

    Postoperative knee function assessed using the Hospital for Special Surgery Knee Score (HSS; range 0 to 100, with higher scores indicating better knee function) or the Knee Society Score (KSS; range 0 to 100, with higher scores indicating better outcome).

  4. Quality of Life and Patient-Reported Outcomes

    Time frame: 1 month, 3 months, 6 months, 3 years, and 5 years after surgery

    Quality of life and patient-reported outcomes assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC; total score range 0 to 96, with higher scores indicating worse pain, stiffness, and functional limitation) and/or the EuroQol 5-Dimension questionnaire (EQ-5D; higher index scores indicating better health status, depending on the value set applied).

  5. Direct Medical Costs

    Time frame: From hospitalization through 5 years after surgery

    Direct medical costs associated with primary unilateral total knee arthroplasty, including total hospitalization cost, prosthesis material cost, medication cost, examination cost, surgery and anesthesia cost, bed and nursing cost, and follow-up cost.

  6. Direct Non-Medical Costs

    Time frame: From hospitalization through 5 years after surgery

    Direct non-medical costs associated with primary unilateral total knee arthroplasty, including caregiver expenses, transportation costs, and accommodation costs for non-local medical visits.

  7. Indirect Costs

    Time frame: From hospitalization through 5 years after surgery

    Indirect costs associated with primary unilateral total knee arthroplasty, including productivity loss where available.

  8. Incremental Cost-Effectiveness Ratio

    Time frame: At end of analysis

    Cost-effectiveness evaluated by incremental cost-effectiveness ratio (ICER), including the cost required for each 1-point improvement in the Hospital for Special Surgery (HSS) score.

  9. Postoperative Adverse Events

    Time frame: From surgery through 5 years after surgery

    All postoperative adverse events recorded during the study follow-up period.

Study contacts

Contact information is provided by the study sponsor or research team.

Ting Li, MD, PhD

CONTACT

[email protected]

86+13587876896

Xiaoyun Pan, MD, PhD

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Second Affiliated Hospital of Wenzhou Medical University

Other

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2030
First posted
Apr 28, 2026
Registry last updated
Apr 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.